Clinical Trials Directory

Trials / Conditions / Rotavirus Vaccines

Rotavirus Vaccines

14 registered clinical trials studyying Rotavirus Vaccines.

StatusTrialSponsorPhase
CompletedROTA-biotic: Measuring the Impact of Rotavirus Vaccines on Paediatric Antibiotic Usage
NCT06882070
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
UnknownUsing "Decision Aids" to Help the Infant Family to Decide the Use of Oral Rotavirus Vaccine
NCT03804489
Taipei Medical University Shuang Ho HospitalN/A
CompletedSafety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Fr
NCT05037435
Limited Liability Company Pharm AidPhase 3
CompletedThis Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix
NCT03207750
GlaxoSmithKlinePhase 3
CompletedEvaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine
NCT02914184
GlaxoSmithKlinePhase 3
CompletedStudy to Assess the Impact of Vaccination on Hospitalizations and Outpatient Visits Due to Rotavirus Gastroent
NCT01733862
GlaxoSmithKline
CompletedPilot Study of the Rotavirus Vaccine in Infants With Intestinal Failure
NCT00995813
Seattle Children's HospitalPhase 4
CompletedStudy to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine in Korean Infants
NCT00969228
GlaxoSmithKlinePhase 4
UnknownCost-Effectiveness Analysis of Rotavirus Vaccination for Children in Korea
NCT00669929
Yonsei University
CompletedEffectiveness Study of GSK Biologicals' Rotarix TM Vaccine in Hospitalized Children
NCT01177826
GlaxoSmithKline
CompletedIntussusception Surveillance After Rotarix Introduction in Mexico
NCT00595205
GlaxoSmithKline
CompletedEfficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants
NCT00480324
GlaxoSmithKlinePhase 3
CompletedA Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy
NCT00432380
GlaxoSmithKlinePhase 2
CompletedTo Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6
NCT00353366
GlaxoSmithKline